CD BioSciences Launches Comprehensive Anti-Aging Drug Development Service Package

CD BioSciences recently launched a complete one-stop anti-aging drug development service package for pharmaceutical companies, research institutions and academic investigators developing cutting-edge anti-aging drugs. The company combines cutting-edge technical platforms with industry-leading experience to support partners throughout the entire anti-aging drug development cycle, from early discovery to preclinical stages. At the core of CD BioSciences' offerings is its diversified anti-aging drug discovery services, which provide customized solutions for drug discovery across a wide range of targets and drug types. The service covers key molecules and signaling pathways such as AMPK, mTOR, SIRT1, NF-κB, p53, and PI3K, which are closely associated with aging mechanisms. For drug types, it encompasses mainstream anti-aging drug categories including senolytics, senomorphics, calorie restriction mimetics, autophagy inducers, anti-inflammatory drugs, antioxidants, telomerase activators, and mitochondrial modulators.

CD BioSciences' anti-aging drug development services further extend to a complete preclinical development system, covering multiple key links to ensure the scientificity and reliability of drug development data. Its anti-aging pharmacology services include both in vitro and in vivo evaluations to verify the therapeutic efficacy of candidate drugs. The in vitro ADME services and in vivo pharmacokinetic services enable early assessment of the pharmacokinetic behaviors of drugs, while the in vitro toxicity testing, non-GLP toxicology, and safety pharmacology services comprehensively evaluate potential toxic effects on key physiological systems. As a specialized aging disease model CRO, CD BioSciences has built a comprehensive and customizable preclinical aging model platform. The model customization services cover four major categories, including organ-specific aging models, general aging models, longevity models, and aging-related disease models. These models can effectively assist clients in uncovering aging mechanisms, validating therapeutic targets, and evaluating the efficacy and safety of anti-aging drugs. More information about their services can be found at https://www.cd-biosciences.com.

CD BioSciences has long been committed to longevity and anti-aging research, and the launch of the one-stop anti-aging drug development services addresses the key challenges of lengthy timelines and high barriers to entry in anti-aging R&D. The company will continue to optimize its technical platforms and service systems and strive to become a top-selected partner for worldwide institutions in the field of anti-aging drug development, promoting the innovation and transformation of anti-aging therapeutics. This comprehensive approach matters because it streamlines the complex process of anti-aging drug development, potentially accelerating the discovery and validation of treatments that could extend healthy human lifespan. The implications are significant for pharmaceutical companies and research institutions seeking to overcome traditional hurdles in aging research, as the integrated service model could reduce development costs and timeframes while improving scientific rigor. By providing access to specialized aging models and comprehensive testing services, CD BioSciences enables more efficient translation of anti-aging research into viable therapeutic candidates, potentially advancing the entire field of longevity medicine.